Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.
AUTOR(ES)
Mehl, J K
RESUMO
Two antilipidemic compounds, clofibrate and procetofene, inhibited the replication of herpes simplex virus type 1 (HSV-1) in African green monkey kidney cells. Clofibrate, at a concentration of 400 mumol/liter caused a 63% reduction (P < 0.001) in HSV-1 yield and at 100 mumol/liter caused a 62% reduction (P < 0.001) in plaque formation. Two stereoisomeric analogs of clofibric acid, (-)- and (+)-desmethyl clofibric acid, also caused a significant inhibition of HSV-1 replication. Procetofene at 5 mumol/liter caused a 56% reduction (P < 0.001) in HSV-1 plaques and at 10 mumol/liter caused a significant reduction (P < 0.001) in both viral yield (42 to 54%) and plaque formation (65%). Procetofene also inhibited the development of HSV-1 plaques. A concentration of 5 mumol/liter resulted in a 26% reduction (P < 0.001) in plaque diameter. Because of their nonspecific inhibitory effect on the uptake of cellular macromolecular precursors for nucleic acid and protein biosynthesis, these antilipidemic compounds may exert their antiviral activity by affecting one or more key metabolic host cell pathways.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=283982Documentos Relacionados
- Antiviral activity of tunicamycin on herpes simplex virus.
- Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds.
- Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
- Deoxyribopyrimidine triphosphatase activity specific for cells infected with herpes simplex virus type 1.
- Oligomeric structure of glycoproteins in herpes simplex virus type 1.
